Compare ACHC & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHC | ALVO |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | ACHC | ALVO |
|---|---|---|
| Price | $16.32 | $4.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $33.75 | $10.67 |
| AVG Volume (30 Days) | ★ 2.7M | 815.9K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | 0.24 |
| Revenue | ★ $3,265,548,000.00 | $573,350,000.00 |
| Revenue This Year | $7.20 | $34.94 |
| Revenue Next Year | $6.65 | $39.55 |
| P/E Ratio | ★ $14.29 | $20.15 |
| Revenue Growth | 4.58 | ★ 45.55 |
| 52 Week Low | $14.30 | $4.70 |
| 52 Week High | $47.08 | $13.70 |
| Indicator | ACHC | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 29.18 |
| Support Level | $14.33 | $5.05 |
| Resistance Level | $17.45 | $5.49 |
| Average True Range (ATR) | 0.81 | 0.27 |
| MACD | 0.31 | 0.04 |
| Stochastic Oscillator | 51.65 | 0.50 |
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.